Proactive Investors - Run By Investors For Investors

AstraZeneca rises as Brilinta medicine meets goal in Phase III clinical trial

The company said during the trial Brilinta, when taken in conjunction with aspirin, had shown “a statistically-significant reduction” in major adverse cardiovascular events, such as heart attacks or strokes, compared to taking aspirin alone
Clinical Trial
The trial, which began in early 2014, involved 19,000 patients across 42 countries

FTSE 100 drug giant AstraZeneca PLC (LON:AZN) shares moved up in early afternoon Monday after its Brilinta treatment met its primary endpoint in a Phase III clinical trial.

The company said during the trial Brilinta, when taken in conjunction with aspirin, had shown “a statistically-significant reduction” in major adverse cardiovascular events, such as heart attacks or strokes, compared to taking aspirin alone.

READ: AstraZeneca posts first rise in annual product sales for almost ten years

The trial, which began in early 2014, involved 19,000 patients suffering from coronary artery disease and type-2 diabetes across 42 countries.

Brilinta is one of Astra’s most important medicines having generated around US$1.6bn in sales 2018, 6% of its overall product total for the year.

In a note to clients, analysts at broker Shore Capital retained their ‘Buy’ rating on the stock, saying consensus forecasts saw Brilinta generating US$1.8bn in sales by 2023.

The broker added that the companies “strong growth” was underpinned by several on-market products, including Brilinta, and that the results from the trial confirmed their confidence in the commercial potential of the drug.

Shares were up 1.2% at 6,232p.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use